Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Resverlogix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Resverlogix Receives FDA Breakthrough Therapy for Apabetalone","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Resverlogix"},{"company":"Resverlogix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Resverlogix Announces Publication of Key Apabetalone Study BETonMACE in the Journal of the American Medical Association","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Resverlogix"},{"company":"Resverlogix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Resverlogix Announces Key BETonMACE Renal Data from Plenary Session Presentation at ERA-EDTA Virtual Congress","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Resverlogix"},{"company":"Resverlogix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Resverlogix"},{"company":"Resverlogix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Resverlogix Publishes New Data Highlighting Apabetalone\u2019s Benefit in Non-alcoholic Fatty Liver Disease","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Resverlogix"}]

Resverlogix

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Resverlogix Publishes New Data Highlighting Apabetalone’s Benefit in Non-alcoholic Fatty Liver Disease

Details:

Apabetalone (RVX000222), is a first-in-class, small molecule, therapeutic candidate with an epigenetic mechanism of action. It is a BD2 (bromodomain) selective BET (bromodomain and extra-terminal) inhibitor that works in preventing and treating disease progression.

Lead Product(s): Apabetalone,Atorvastatin,Rosuvastatin

Therapeutic Area: Endocrinology Product Name: RVX000222

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 22, 2022

ASK
US

Upload
your Pipeline Activity

Resverlogix

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study

Details:

The FDA has accepted Resverlogix BETonMACE2 clinical plan as a registration enabling study with positive implications for Resverlogix and its ongoing partnership discussions.

Lead Product(s): Apabetalone,Atorvastatin

Therapeutic Area: Endocrinology Product Name: RVX000222

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 22, 2020

ASK
US

Upload
your Pipeline Activity

Resverlogix

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Resverlogix Announces Key BETonMACE Renal Data from Plenary Session Presentation at ERA-EDTA Virtual Congress

Details:

For the first time in patients with a recent Acute Coronary Syndrome with diabetes and stage 3 CKD co-morbidities, we observed a 50% reduction of MACE by a medication, apabetalone treatment.

Lead Product(s): Apabetalone,Atorvastatin

Therapeutic Area: Endocrinology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 09, 2020

ASK
US

Upload
your Pipeline Activity

Resverlogix

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Resverlogix Announces Publication of Key Apabetalone Study BETonMACE in the Journal of the American Medical Association

Details:

Apabetalone recently completed the first ever Phase 3 clinical trial of a BET inhibitor for a cardiovascular disease indication.

Lead Product(s): Apabetalone,Atorvastatin

Therapeutic Area: Endocrinology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 30, 2020

ASK
US

Upload
your Pipeline Activity

Resverlogix

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Resverlogix Receives FDA Breakthrough Therapy for Apabetalone

Details:

FDA has granted Breakthrough Therapy Designation for apabetalone in combination with high-intensity statins, for the secondary prevention of MACE in patients with type 2 DM and recent ACS.

Lead Product(s): Apabetalone

Therapeutic Area: Endocrinology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 03, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY